These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 20035739

  • 1. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
    McClean PL, Gault VA, Harriott P, Hölscher C.
    Eur J Pharmacol; 2010 Mar 25; 630(1-3):158-62. PubMed ID: 20035739
    [Abstract] [Full Text] [Related]

  • 2. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid.
    Gault VA, Hölscher C.
    Eur J Pharmacol; 2008 Jun 10; 587(1-3):112-7. PubMed ID: 18466898
    [Abstract] [Full Text] [Related]

  • 3. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.
    Abbas T, Faivre E, Hölscher C.
    Behav Brain Res; 2009 Dec 14; 205(1):265-71. PubMed ID: 19573562
    [Abstract] [Full Text] [Related]

  • 4. Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats.
    Wang XH, Li L, Hölscher C, Pan YF, Chen XR, Qi JS.
    Neuroscience; 2010 Nov 10; 170(4):1239-48. PubMed ID: 20727946
    [Abstract] [Full Text] [Related]

  • 5. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL, Hölscher C.
    Neuropharmacology; 2014 Jan 10; 76 Pt A():57-67. PubMed ID: 23973293
    [Abstract] [Full Text] [Related]

  • 6. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.
    Gengler S, McClean PL, McCurtin R, Gault VA, Hölscher C.
    Neurobiol Aging; 2012 Feb 10; 33(2):265-76. PubMed ID: 20359773
    [Abstract] [Full Text] [Related]

  • 7. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
    McClean PL, Hölscher C.
    Neuropharmacology; 2014 Nov 10; 86():241-58. PubMed ID: 25107586
    [Abstract] [Full Text] [Related]

  • 8. Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats.
    Han WN, Hölscher C, Yuan L, Yang W, Wang XH, Wu MN, Qi JS.
    Neurobiol Aging; 2013 Feb 10; 34(2):576-88. PubMed ID: 22592020
    [Abstract] [Full Text] [Related]

  • 9. Glucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodents.
    Iwai T, Sawabe T, Tanimitsu K, Suzuki M, Sasaki-Hamada S, Oka J.
    J Neurosci Res; 2014 Apr 10; 92(4):446-54. PubMed ID: 24464856
    [Abstract] [Full Text] [Related]

  • 10. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
    Holscher C.
    Recent Pat CNS Drug Discov; 2010 Jun 10; 5(2):109-17. PubMed ID: 20337586
    [Abstract] [Full Text] [Related]

  • 11. Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice.
    Porter D, Faivre E, Flatt PR, Hölscher C, Gault VA.
    Peptides; 2012 May 10; 35(1):1-8. PubMed ID: 22465882
    [Abstract] [Full Text] [Related]

  • 12. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain.
    Hamilton A, Patterson S, Porter D, Gault VA, Holscher C.
    J Neurosci Res; 2011 Apr 10; 89(4):481-9. PubMed ID: 21312223
    [Abstract] [Full Text] [Related]

  • 13. The role of GLP-1 in neuronal activity and neurodegeneration.
    Hölscher C.
    Vitam Horm; 2010 Apr 10; 84():331-54. PubMed ID: 21094907
    [Abstract] [Full Text] [Related]

  • 14. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.
    Porter WD, Flatt PR, Hölscher C, Gault VA.
    Int J Obes (Lond); 2013 May 10; 37(5):678-84. PubMed ID: 22665137
    [Abstract] [Full Text] [Related]

  • 15. Val⁸-GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid β peptide in rats.
    Wang XH, Yang W, Hölscher C, Wang ZJ, Cai HY, Li QS, Qi JS.
    J Neurosci Res; 2013 Apr 10; 91(4):568-77. PubMed ID: 23335292
    [Abstract] [Full Text] [Related]

  • 16. Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain.
    McGovern SF, Hunter K, Hölscher C.
    Brain Res; 2012 Sep 14; 1473():204-13. PubMed ID: 22867941
    [Abstract] [Full Text] [Related]

  • 17. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain.
    Parthsarathy V, Hölscher C.
    Eur J Pharmacol; 2013 Jan 30; 700(1-3):42-50. PubMed ID: 23276669
    [Abstract] [Full Text] [Related]

  • 18. [Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease].
    Wang XH, Yang W, Qi JS.
    Sheng Li Xue Bao; 2010 Oct 25; 62(5):398-406. PubMed ID: 20945041
    [Abstract] [Full Text] [Related]

  • 19. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
    Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J.
    Expert Opin Ther Targets; 2011 Oct 25; 15(10):1153-62. PubMed ID: 21749267
    [Abstract] [Full Text] [Related]

  • 20. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.
    Regul Pept; 2012 Nov 10; 179(1-3):91-100. PubMed ID: 22989472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.